12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
Two years ago, TSW reported on several cases in which corporations outside of California successfull...
Read More >
The ECB was even more aggressive than expected in its moves to “head off a downturn before it gaine...
Read More >
The UK's departure from the EU on 31 January has initiated an 11 month transition period, during whi...
Read More >
Compliance into the Weeds is the only weekly podcast which takes a deep dive into a compliance relat...
Read More >
The Federal Trade Commission (“FTC”) has announced the annual revisions to the Hart-Scott-Rodino A...
Read More >
Illinois legislature recently approved the Workplace Transparency Act (WTA) – a sweeping piece of l...
Read More >